What Next for GENMAB A/S ORDINARY SHARES (OTCMKTS:GNMSF) Stock After Increase in Shorted Shares?

May 27, 2018 - By Darrin Black

Genmab A/S (OTCMKTS:GNMSF) Logo

The stock of GENMAB A/S ORDINARY SHARES (OTCMKTS:GNMSF) registered an increase of 3.71% in short interest. GNMSF’s total short interest was 645,200 shares in May as published by FINRA. Its up 3.71% from 622,100 shares, reported previously. With 400 shares average volume, it will take short sellers 1613 days to cover their GNMSF’s short positions. The short interest to GENMAB A/S ORDINARY SHARES’s float is 1.07%.

The stock decreased 12.10% or $24.75 during the last trading session, reaching $179.75. About 1,001 shares traded or 456.11% up from the average. Genmab A/S (OTCMKTS:GNMSF) has 0.00% since May 27, 2017 and is . It has underperformed by 11.55% the S&P500.

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company has market cap of $10.46 billion. The firm markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia ; and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM). It has a 52.67 P/E ratio. The Company’s products under development include Ofatumumab to treat CLL and follicular lymphoma; Ofatumumab (OMB157) for relapsing remitting multiple sclerosis; and Daratumumab to treat MM, Non-Hodgkin's lymphoma, and solid tumors, as well as natural killer/T-cell lymphoma, nasal type.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.